

Please cancel claim 15 without prejudice.

16. (amended) [The screening] A method of screening substances for a substance for treatment of a disease caused by an aberrant [gene product] receptor comprising bringing an aberrant [gene product] receptor into contact [and] with a [subject] substance and assaying the operation activity of said substance on said product.

ent E3
C2
~~17. (amended) A method of screening for a drug for restoring normal function to a signal transduction system of a cell having an aberrant receptor of a mammal suffering from a disease caused by the aberrant receptor, which comprises bringing the aberrant receptor into contact with a subject substance and assaying the activity of said substance on said receptor and wherein the activity is an activity that restores the normal function of the cell.~~

18. (amended) The screening method according to claim 16, wherein the aberrant receptor is [an aberrant receptor prepared by expressing in] isolated from a cell which expresses the gene encoding the aberrant receptor.

19. (amended) The screening method according to claim 16, wherein [the gene encoding the aberrant receptor is an aberrant receptor-encoding gene specified by comparative analysis of] the method further comprises the step of selecting the receptor by comparing a gene [prepared] isolated from a cell of a mammal suffering from a disease caused by the aberrant receptor, [and] with a gene prepared from a cell of a mammal of the same species that does not carry the aberrant receptor.

Please cancel claim 20, without prejudice.

C3
21. (amended) A method of preparing a substance for treatment of a disease caused by an aberrant receptor [which comprises] which results in the substantial reduction in activity of the signal transduction system of cells having the aberrant receptor, the method comprising:

selecting a substance from subject substances by bringing the aberrant receptor into contact with a subject substance,
assaying the activity of said substance on said [product] receptor,
selecting a substance that substantially operates the signal transduction system of the cell having the aberrant receptor wherein said activity is activity that restores wide-type activity of the receptor and

preparing [a] the selected substance in a pharmaceutical composition [judged to substantially operate the signal transduction system of a cell having the aberrant gene product wherein said activity is activity that restores wide-type activity to the receptor].

22. (amended) The method according to claim 21, wherein the aberrant receptor is [an aberrant receptor prepared by expressing in] isolated from a cell which expresses the gene encoding the aberrant receptor.

23. (amended) The method according to claim 22, wherein the method further comprises selecting the gene encoding the aberrant receptor [is an aberrant receptor-encoding gene specified by comparative analysis of] by comparing a gene prepared from a cell of a mammal suffering from a disease caused by the aberrant receptor[, and] with a gene prepared from a cell of a mammal of the same species that does not carry the aberrant receptor.

24. (amended) A method of screening for a substance capable of [operating] causing an aberrant [gene product] receptor to operate in a manner similar to a non-aberrant receptor comprising: (1)expressing in a cell the gene encoding the aberrant [gene product, separating] receptor, (2) isolating the aberrant [gene product] receptor from the cell, (3) providing a substance [as] to the aberrant [gene product] receptor and, (4) determining the operation activity of said substance [as] on said [gene product] receptor.

Please cancel claim 25, without prejudice.